Episode 116 – Drug Pricing and Market Access: CMS Update With Rujul Desai
About this episode
Rujul Desai discusses CMS priorities and the transition from big law to government in the context of drug pricing and market access.
The Trump administration has advanced many policy initiatives in the drug pricing and market access area, and CMS —the Centers for Medicare & Medicaid Services — is the agency at the heart of many of these efforts. Rujul Desai, Senior Counselor to CMS and former Deputy General Counsel at the Department of Health & Human Services, joins Washington, D.C. partner Chris Schott and associate Danny Machado for an update on key CMS priorities. Rujul also discusses the transition from big law to government and shares practice pointers for engaging with the agency. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox. This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified…
More episodes of Connected With Latham
- Episode 121 – The Growth Rocketship: Inside Boutique Venture With NewView Capital
- Episode 120 – The Growth Rocketship: Modernizing Real Estate With Opendoor
- Episode 119 – The Growth Rocketship: How Rakuten Capital Masters Diplomatic Capitalism
- Episode 118 – The Growth Rocketship: Axiado Takes Cybersecurity Inside the Rack
- Episode 117 – The Growth Rocketship: Using AI to Accelerate Analog Semiconductor Design With Celera
Explore listener stats, chart rankings, contacts and more on the Connected With Latham podcast page.